Literature DB >> 12088174

Risk of cardiovascular disease and sudden death in schizophrenia.

Michael Davidson1.   

Abstract

Patients with schizophrenia are at higher risk for medical illnesses than people in the general population. Electrocardiographic and metabolic abnormalities that occur in patients with schizophrenia who are treated with antipsychotic medications have raised concerns about the safety of these medications. Concerns are amplified by the increased risk of atherosclerosis and sudden cardiac death in patients with schizophrenia regardless of the effect of antipsychotic agents. Because the modifiable risk factors for coronary atherosclerosis and sudden death are so prevalent within the schizophrenic population, it is important for clinicians treating patients with schizophrenia to know what these risks are and understand how they can contribute to increased mortality in these patients. The increased risk of atherosclerosis and sudden death in the schizophrenic population highlights a need for preventive services, which is further underscored by the numerous system- and patient-related barriers to preventive treatment. Clinicians must not only be aware of the modifiable risk factors, but they must also learn to manage the obstacles to prevention in conjunction with other health care specialists.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12088174

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN: 0160-6689            Impact factor:   4.384


  23 in total

1.  Conditional calcineurin knockout mice exhibit multiple abnormal behaviors related to schizophrenia.

Authors:  Tsuyoshi Miyakawa; Lorene M Leiter; David J Gerber; Raul R Gainetdinov; Tatyana D Sotnikova; Hongkui Zeng; Marc G Caron; Susumu Tonegawa
Journal:  Proc Natl Acad Sci U S A       Date:  2003-07-08       Impact factor: 11.205

Review 2.  Role of the Sympathetic Nervous System in Stress-Mediated Cardiovascular Disease.

Authors:  Dagmara Hering; Kamila Lachowska; Markus Schlaich
Journal:  Curr Hypertens Rep       Date:  2015-10       Impact factor: 5.369

Review 3.  Atypical antipsychotics: from potassium channels to torsade de pointes and sudden death.

Authors:  Karine Titier; Pierre-Olivier Girodet; Hélène Verdoux; Mathieu Molimard; Bernard Bégaud; Wilhelm Haverkamp; Malcolm Lader; Nicholas Moore
Journal:  Drug Saf       Date:  2005       Impact factor: 5.606

4.  Heart disease, schizophrenia, and affective psychoses: epidemiology of risk in primary care.

Authors:  Suzanne McDermott; Robert Moran; Tan Platt; Terri Isaac; Hope Wood; Srikanth Dasari
Journal:  Community Ment Health J       Date:  2005-12

5.  Inflammation markers in individuals with history of mental health crisis.

Authors:  Dan Justo; Yaron Arbel; Gal Altberg; Michael Kinori; Arie Shirom; Samuel Melamed; Itzhak Shapira; Ori Rogowski
Journal:  Inflammation       Date:  2008-08       Impact factor: 4.092

Review 6.  The spectrum of epidemiology underlying sudden cardiac death.

Authors:  Meiso Hayashi; Wataru Shimizu; Christine M Albert
Journal:  Circ Res       Date:  2015-06-05       Impact factor: 17.367

7.  Family practice enhancements for patients with severe mental illness.

Authors:  Patricia Pastore; Kim S Griswold; Gregory G Homish; Robert Watkins
Journal:  Community Ment Health J       Date:  2012-07-24

8.  Change in framingham risk score in patients with schizophrenia: a post hoc analysis of a randomized, double-blind, 6-week trial of ziprasidone and olanzapine.

Authors:  Megan C Del Valle; Antony D Loebel; Stephen Murray; Ruoyong Yang; David J Harrison; Brian J Cuffel
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2006

Review 9.  Are there modifiable risk factors which will reduce the excess mortality in schizophrenia?

Authors:  Hiram Joseph Wildgust; Mike Beary
Journal:  J Psychopharmacol       Date:  2010-11       Impact factor: 4.153

10.  Matrix Metalloproteinase-9 (MMP9)-A Mediating Enzyme in Cardiovascular Disease, Cancer, and Neuropsychiatric Disorders.

Authors:  Janusz K Rybakowski
Journal:  Cardiovasc Psychiatry Neurol       Date:  2009-08-31
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.